213 related articles for article (PubMed ID: 34703212)
1. The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study.
Walling DP; Hassman HA; Anta L; Ochoa L; Ayani I; Martínez J; Gutierro I
Drug Des Devel Ther; 2021; 15():4371-4382. PubMed ID: 34703212
[TBL] [Abstract][Full Text] [Related]
2. A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia.
Anta L; Llaudó J; Ayani I; Martínez J; Litman RE; Gutierro I
Int Clin Psychopharmacol; 2018 Mar; 33(2):79-87. PubMed ID: 29112001
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia.
Eerdekens M; Van Hove I; Remmerie B; Mannaert E
Schizophr Res; 2004 Sep; 70(1):91-100. PubMed ID: 15246468
[TBL] [Abstract][Full Text] [Related]
4. Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review.
Álamo C
Adv Ther; 2022 Nov; 39(11):4875-4891. PubMed ID: 36048404
[TBL] [Abstract][Full Text] [Related]
5. Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability.
Thyssen A; Remmerie B; D'Hoore P; Kushner S; Mannaert E
Clin Ther; 2007 Feb; 29(2):290-304. PubMed ID: 17472821
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study.
Filts Y; Litman RE; Martínez J; Anta L; Naber D; Correll CU
Schizophr Res; 2022 Jan; 239():83-91. PubMed ID: 34847501
[TBL] [Abstract][Full Text] [Related]
7. Comparative fasting bioavailability of dispersible and conventional tablets of risperidone: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy male Chinese volunteers.
Huang M; Shen-Tu J; Hu X; Chen J; Liu J; Wu L
Clin Ther; 2012 Jun; 34(6):1432-9. PubMed ID: 22595151
[TBL] [Abstract][Full Text] [Related]
8. Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1).
Llaudó J; Anta L; Ayani I; Martínez J; Schronen J; Morozova M; Ivanov M; Gutierro I
Int Clin Psychopharmacol; 2016 Nov; 31(6):323-31. PubMed ID: 27416102
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment.
Laffont CM; Gomeni R; Zheng B; Heidbreder C; Fudala PJ; Nasser AF
Clin Pharmacokinet; 2014 Jun; 53(6):533-43. PubMed ID: 24464285
[TBL] [Abstract][Full Text] [Related]
10. Risperidone: effects of formulations on oral bioavailability.
Gutierrez R; Lee PI; Huang ML; Woestenborghs R
Pharmacotherapy; 1997; 17(3):599-605. PubMed ID: 9165565
[TBL] [Abstract][Full Text] [Related]
11. Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses.
Reyes JF; Preskorn SH; Khan A; Kumar D; Cullen EI; Perdomo CA; Pratt RD
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):50-7. PubMed ID: 15496223
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Safety of Risperidone Subcutaneous Implants in Stable Patients With Schizophrenia.
Dammerman R; Kim S; Adera M; Schwarz A
Clin Pharmacol Drug Dev; 2018 Mar; 7(3):298-310. PubMed ID: 29420868
[TBL] [Abstract][Full Text] [Related]
13. Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers.
Belotto KC; Raposo NR; Ferreira AS; Gattaz WF
Clin Ther; 2010 Nov; 32(12):2106-15. PubMed ID: 21118746
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia.
Gefvert O; Eriksson B; Persson P; Helldin L; Björner A; Mannaert E; Remmerie B; Eerdekens M; Nyberg S
Int J Neuropsychopharmacol; 2005 Mar; 8(1):27-36. PubMed ID: 15710053
[TBL] [Abstract][Full Text] [Related]
15. Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients.
Thyssen A; Rusch S; Herben V; Quiroz J; Mannaert E
J Clin Pharmacol; 2010 Sep; 50(9):1011-21. PubMed ID: 20097933
[TBL] [Abstract][Full Text] [Related]
16. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone.
Gomeni R; Heidbreder C; Fudala PJ; Nasser AF
J Clin Pharmacol; 2013 Oct; 53(10):1010-9. PubMed ID: 23868656
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration.
Mannaert E; Vermeulen A; Remmerie B; Bouhours P; Levron JC
Encephale; 2005; 31(5 Pt 1):609-15. PubMed ID: 16598965
[TBL] [Abstract][Full Text] [Related]
18. Changes in plasma concentrations of risperidone and 9-hydroxyrisperidone and the associated clinical effects during the switch from oral risperidone to extended-release paliperidone tablets in patients with schizophrenia.
Yang DS; Seong SJ; Yoon YR; Lim MS; Kwak KH; Lee SJ
J Psychopharmacol; 2014 Apr; 28(4):341-8. PubMed ID: 24346811
[TBL] [Abstract][Full Text] [Related]
19. Open-Label Crossover Oral Bioequivalence Pharmacokinetics Comparison for a 3-Day Loading Dose Regimen and 15-Day Steady-State Administration of SUBA-Itraconazole and Conventional Itraconazole Capsules in Healthy Adults.
Thompson GR; Lewis P; Mudge S; Patterson TF; Burnett BP
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32457106
[TBL] [Abstract][Full Text] [Related]
20. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication.
Nesvåg R; Hendset M; Refsum H; Tanum L
Acta Psychiatr Scand; 2006 Jul; 114(1):21-6. PubMed ID: 16774657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
